Jason T. Gammack
With over 25 years of experience in the life science and molecular diagnostic industry, I am a founder, investor, and advisor who helps innovative biotech companies achieve their full potential. I am currently the founder and managing director of JTG Investments & Advisory UG, a firm that provides strategic and financial guidance to emerging and established biotech companies in Europe and the US. Previously, I was the co-founder and CEO of Resolve BioSciences, a company that developed a revolutionary technology for spatial omics and single-cell analysis. I led the company from inception to acquisition, securing multiple rounds of funding, building a strong team, and launching the first product in the market. I also held senior executive roles at Inscripta, QIAGEN, Ingenuity Systems, and Affymetrix, where I drove the commercialization of disruptive life science tools and solutions, from concept to market ownership. I have a proven track record of increasing sales and growing the bottom line, while spearheading operational improvements and marketing strategies. I am passionate about bringing cutting-edge technologies and solutions to the life science research and clinical communities, and enabling them to advance scientific discovery and improve human health. I am an inspirational leader and dynamic storyteller who clearly articulates the vision and value proposition of the business, and empowers the team to achieve success. I excel in dynamic, demanding environments, while remaining pragmatic and focused. I am always looking for new opportunities and challenges to leverage my expertise and network, and to make a positive impact in the biotech sector.
Ansa Biotechnologies
Revolutionizing the Customer Experience Through Seamless Access to Synthetic DNA
-
What happens in synthetic biology when a DNA synthesis company actually delivers what scientists really want? Discover how a next-generation platform is redefining DNA synthesis to meet the real needs of today’s scientists. By combining cutting-edge synthesis technology with a highly collaborative service model, advanced platforms are helping researchers move faster, access hard-to-get sequences, and expand their design space like never before. Join this talk to learn how to push the boundaries of what's possible, unlock new designs, and accelerate your next breakthrough.
Reading and Writing: How Far, How Fast, & When?
-
This session will examine the frontiers of genomic sequencing and synthesis, providing a critical assessment of the present capabilities and charting likely trajectories for future progress. Participants will highlight the latest advances in instrumentation, informatics, and automation that are pushing beyond conventional limits, while also considering emerging technologies poised to reshape the landscape of DNA reading and writing. By focusing on accuracy, throughput, and scalability, this discussion will illuminate the fundamental shifts now taking place and the new horizons they open for biological research and innovation.